HCV RNA viral load assessments in the era of direct-acting antivirals

American Journal of Gastroenterology

Volumn 108, Issue 4, 2013, Pages 471-475

  Cobb, Bryan ^a   Pockros, Paul J ^b   Vilchez, Regis A ^a   Vierling, John M ^c  

^a ROCHE MOLECULAR SYSTEMS   (United States)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DIRECT ACTING ANTIVIRAL AGENT; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL THERAPY; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TREATMENT DURATION; VIRUS CONCENTRATION; VIRUS DETECTION; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 84875925389     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.248     Document Type: Review

References (24)

1. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011;17:116-21.
2. Cobb B, Vaks JE, Do T et al. Evolution in the sensitivity of quantitative HIV-1 viral load tests. J Clin Virol 2011;52S:S77-82.
3. Caliendo AM, Valsamakis A, Bremer JW et al. Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification. J Clin Microbiol 2011;49:2854-8.
4. World Health Organization. Hepatitis C http://www.who.int/entity/ mediacentre/factsheets/fs164/en/(2012).
5. Freeman RB, Steffick DE, Guidinger MK et al. Liver and intestine transplantation in the United States 1997-2006. Am J Transplant 2008;8:958-76.
6. Davila JA, Morgan RO, Shaib Y et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population based study. Gastroenterology 2004;127:1372-80.
7. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
8. Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
9. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
10. Poordad F, McCone J, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
11. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
12. Jacobson IM, McHutchinson JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
13. Clinical and Laboratory Standards Institute. Protocols for Determination of Limits of Detection and Limits of Quantification. Approved guideline. CLSI document EP17-A (ISBN 1562385518). Wayne, PA, 2004.
14. COBAS TaqMan HCV Test, version 2, For Use With the High Pure System [US FDA-approved package insert]. Roche Molecular Diagnostics (Pleasanton, CA): 2010, Document Rev 1.0.
15. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
16. Sarrazin C, Shiffman ML, Hadziyannis SJ et al. Definition of rapid virological response with a highly sensitive real time PCR based HCV RNA assay in peginterferon alfa-2a plus ribavirin response guided therapy. J Hepatology 2010;52:832-8.
17. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44.
18. Cobb B, Vilchez RA. An update on treatment of HCV genotype 1 and viral load assessments. Hepatology 2012;55:979-80.
19. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012;55:1048-57.
20. Pockros P. Drugs in development for viral hepatitis: a promising future. Expert Opin Biol Ther 2011;12:1611-22.
21. Merck. Victrelis (boceprevir) [prescribing information] http://www.merck. com/product/usa/pi-circulars/v/victrelis/victrelis-pi.pdf (2011).
22. Vertex. Incivek (telaprevir) [prescribing information] http://pi.vrtx.com/files/uspi-telaprevir.pdf (2011).
23. Michelin BDA, Muller Z, Stelzl E et al. Evaluation of the Abbot real time assay for quantitative detection of hepatitis C RNA. J Clin Virol 2007;38:96-100.
24. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature 2009;461:399-401.